Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multi-centered, Two-stage Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine in the First Line Treatment of Advanced mCRC Patients Unfit for Intense Therapy

NCT06195670 is registered in ClinicalTrials.gov with Zhejiang Cancer Hospital as lead sponsor.

NCT NCT06195670
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06195670 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multi-centered, Two-stage Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine in the First Line Treatment of Advanced mCRC Patients Unfit for Intense Therapy
Lead sponsor
Zhejiang Cancer Hospital
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
January 31, 2024
Completion date
January 31, 2027
Enrollment
220 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

crc, metastatic colorectal adenocarcinoma, metastatic colorectal cancer